Hydrochloric Acid

Hydrochloric Acid

SCHEMBL675415

OC[C@H]1O[C@@H](Oc2cc3c(O)cc(O)cc3[o+]c2-c2cc(O)c(O)c(O)c2)[C@H](O)[C@@H](O)[C@@H]1O.[Cl-]

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 4/20 0.80
DPP4 P27487 2/20 0.80
F2 P00734 1/20 0.71
EGFR P00533 2/20 0.50
KDR P35968 2/20 0.50
SNCA P37840 2/20 0.50
GLO1 Q04760 2/20 0.50
EP300 Q09472 2/20 0.50
CREBBP Q92793 2/20 0.50
EPHX2 P34913 1/20 0.49
SLC28A3 Q9HAS3 3/20 0.48
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
AKR1B1 P15121 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.45
MAOA P21397 1/20 0.45
TYR P14679 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31213251 1.00 CD38 (0.80) CD38DPP4F2EGFRKDR
Hydrochloric Acid SCHEMBL29374214 1.00 CD38 (0.80) CD38DPP4F2EGFRKDR
Hydrochloric Acid SCHEMBL29894453 1.00 CD38 (0.80) CD38DPP4F2EGFRKDR
SCHEMBL30185877 0.99 CD38 (0.81) CD38DPP4F2EGFRKDR
SCHEMBL675416 0.99 CD38 (0.81) CD38DPP4F2EGFRKDR
Hydrochloric Acid SCHEMBL318114 0.94 F2 (0.80) CD38DPP4F2EPHX2SLC28A3
Hydrochloric Acid SCHEMBL30437834 0.93 CD38 (0.73) CD38DPP4F2EPHX2SLC28A3
Hydrochloric Acid SCHEMBL29894492 0.93 CD38 (0.73) CD38DPP4F2EPHX2SLC28A3
SCHEMBL318115 0.93 F2 (0.81) CD38DPP4F2EPHX2SLC28A3
Hydrochloric Acid SCHEMBL30438359 0.92 CD38 (0.72) CD38DPP4F2EGFRKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240263203-A1 RECOMBINANT HOST CELLS WITH IMPROVED PRODUCTION OF TETRAKETIDE DERIVATIVES IPTECTOR ASSETS APS (DK) 2024-08-08 US claimed
WO-2023219526-A1 MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT PROKIN MILAN (RS) 2023-11-16 WO claimed
US-20220279829-A1 Use of Anthocyanin-Anionic Polysaccharide Complex for Preventing or Treating Influenza Virus A Infection JBKLAB CO., LTD. (KR) 2022-09-08 US claimed
US-20220249675-A1 Composition for Preventing, Ameliorating, or Treating Gastritis or peptic Ulcer Comprising Anthocyanin-Negatively Charged Polysaccharide Complex as Active Ingredient JBKLAB CO., LTD. (KR) 2022-08-11 US claimed
EP-3978025-A1 COMPOSITION FOR PREVENTING, AMELIORATING, OR TREATING GASTRITIS OR PEPTIC ULCER COMPRISING ANTHOCYANIN-NEGATIVELY CHARGED POLYSACCHARIDE COMPLEX AS ACTIVE INGREDIENT JBKLAB Co., Ltd. (KR) 2022-04-06 EP claimed
EP-3978026-A1 USE OF ANTHOCYANIN-ANIONIC POLYSACCHARIDE COMPLEX FOR PREVENTING OR TREATING INFLUENZA VIRUS A INFECTION JBKLAB Co., Ltd. (KR) 2022-04-06 EP claimed
CN-114040759-A Composition for preventing, ameliorating or treating gastritis or peptic ulcer comprising anthocyanin-negatively charged polysaccharide complex as active ingredient 株式会社张峰根硏究所 2022-02-11 CN claimed
CN-114025754-A Use of anthocyanidin-anionic polysaccharide complex for preventing or treating influenza a virus infection 株式会社张峰根硏究所 2022-02-08 CN claimed
CN-106794214-B Composition containing a mixture of plant extracts or a mixture of molecules contained in said plants 瓦尔比奥蒂斯公司 2021-06-15 CN claimed
CN-111973660-A Composition containing a mixture of plant extracts or of molecules contained in said plants and uses thereof 瓦尔比奥蒂斯公司 2020-11-24 CN claimed
EP-2096172-A2 Genetic sequences having methyltransferase activity and uses therefor International Flower Developments Proprietary Limited (AU) 2009-09-02 EP claimed
US-20090176718-A1 Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome NIH - DEITR 2009-07-09 US claimed
WO-2009059218-A1 BERRY PREPARATIONS FOR TREATMENT OF DIABETES AND METABOLIC SYNDROME PHYTOMEDICS, INC. (US) 2009-05-07 WO claimed
WO-2008016593-A2 BIOACTIVE DEPSIDE AND ANTHOCYANIN COMPOUNDS, COMPOSITIONS, AND METHODS OF USE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2008-02-07 WO claimed
US-20070150984-A1 Genetic sequences having methyltransferase activity and uses therefor INTERNATIONAL FLOWER DEVELOPMENTS PTY.LTD. OF COLLINGWOOD (AU) 2007-06-28 US claimed
EP-1478753-A4 GENETIC SEQUENCES HAVING METHYLTRANSFERASE ACTIVITY AND USES THEREFOR INTERNAT FLOWERS DEVELOPMENTS (AU) 2007-03-28 EP claimed
US-6967032-B2 Mixtures of anthracyanins, monosaccharides, disaccharides MEDPALETT PHARMACEUTICALS AS (NO) 2005-11-22 US claimed
EP-1478753-A1 GENETIC SEQUENCES HAVING METHYLTRANSFERASE ACTIVITY AND USES THEREFOR INTERNATIONAL FLOWER DEVELOPMENTS Pty. Ltd. (AU) 2004-11-24 EP claimed
US-20040131749-A1 Phytochemicals from edible bean process streams ARCHER-DANIELS-MIDLAND COMPANY 2004-07-08 US claimed
WO-2003062428-A1 GENETIC SEQUENCES HAVING METHYLTRANSFERASE ACTIVITY AND USES THEREFOR INTERNATIONAL FLOWER DEVELOPMENTS PTY LTD (AU) 2003-07-31 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176718-A1 Berry Preparations For Treatment Of Diabetes And Metabolic Syndrome GPR119, FABP4, GYS2 CD38 740/4885DPP4 109/4885F2 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.